FDA Approves Venetoclax for CLL or SLL With or Without 17p Deletion After One Prior Therapy

Jun 08

2018

The Food and Drug Administration granted regular approval to venetoclax (VENCLEXTA, AbbVie Inc. and Genentech Inc.) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

Citations

APA

American Society of Hematology. (2018).
FDA Approves Venetoclax for CLL or SLL With or Without 17p Deletion After One Prior Therapy.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2018/fda-approves-venetoclax-cll-sll-17p-deletion-after-one-prior-therapy.

Chicago

American Society of Hematology.
"FDA Approves Venetoclax for CLL or SLL With or Without 17p Deletion After One Prior Therapy." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2018/fda-approves-venetoclax-cll-sll-17p-deletion-after-one-prior-therapy
(label-accessed December 11, 2024).

MLA

"American Society of Hematology."
FDA Approves Venetoclax for CLL or SLL With or Without 17p Deletion After One Prior Therapy, 11 Dec. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2018/fda-approves-venetoclax-cll-sll-17p-deletion-after-one-prior-therapy.

Citation Manager Formats

BibLaTeX
Bookends
EasyBib
EndNote
Mendeley
Papers
RIS
Ref Manager
RefWorks
Zotero

Help ASH Build an Inclusive Hematology Community!

ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.

How Can You Help?

Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!

Update Access to Demographic Information Learn About Our Mission